News
-
Aclarion Announces First Commercial Agreement in Michigan
August 14, 2024 -
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
August 13, 2024 -
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
July 9, 2024 -
Aclarion Announces Initial Payer Coverage of Nociscan by AXA throughout Greater London, UK
June 26, 2024 -
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
June 25, 2024 -
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
June 20, 2024 -
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution
June 18, 2024 -
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
April 25, 2024 -
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
March 4, 2024 -
Aclarion Announces Closing of $3.0 Million Public Offering
February 27, 2024